Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. [electronic resource]
Producer: 19970522Description: S28-31 p. digitalISSN:- 0887-6924
- Adult
- Antimetabolites, Antineoplastic -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Azacitidine -- administration & dosage
- Bone Marrow -- drug effects
- Daunorubicin -- administration & dosage
- Decitabine
- Drug Administration Schedule
- Female
- Humans
- Immunophenotyping
- Infusions, Intravenous
- Karyotyping
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Middle Aged
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.